PMC:7195088 / 9943-10114 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"170","span":{"begin":113,"end":121},"obj":"Species"},{"id":"204","span":{"begin":98,"end":109},"obj":"Chemical"},{"id":"242","span":{"begin":127,"end":135},"obj":"Disease"}],"attributes":[{"id":"A170","pred":"tao:has_database_id","subj":"170","obj":"Tax:9606"},{"id":"A204","pred":"tao:has_database_id","subj":"204","obj":"MESH:C502936"},{"id":"A242","pred":"tao:has_database_id","subj":"242","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"modulatory therapies be administered? Owing to the lack of high-level evidence, administration of tocilizumab to patients with COVID-19 should preferentially occur within "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T51","span":{"begin":127,"end":135},"obj":"Disease"}],"attributes":[{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"modulatory therapies be administered? Owing to the lack of high-level evidence, administration of tocilizumab to patients with COVID-19 should preferentially occur within "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T44","span":{"begin":98,"end":109},"obj":"Chemical"}],"attributes":[{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"modulatory therapies be administered? Owing to the lack of high-level evidence, administration of tocilizumab to patients with COVID-19 should preferentially occur within "}